Tumblelog by Soup.io
Newer posts are loading.
You are at the newest post.
Click here to check if anything new just came in.
alanzspaterson

Health Care Sector Update For 02/09/2015: Achn,atos,tmo,rgls - Nasdaq.com

Health Care Sector Update for 02/09/2015: LJPC,ATOS,TMO,RGLS - NASDAQ.com

In company news, Achillion Pharmaceuticals ( ACHN ) rallied Monday after the specialty drugmaker reported postive interim results from Phase II testing of its ACH-3102 drug candidate combined with 400 milligrams of sofosbuvir, with all you could try this out 12 of the patients with Hepatitis C in the study showing a sustained virological response 12 weeks after treatment. The strong virological response was achieved independent of gender or baseline viral load or the presence of the IL28B genotype that plays a role in interferon signaling. In addition to the 100% response in patients treated with the drug combination for six weeks, all 12 patients in the eight-week treatment arm also continued to show virological response after 24 weeks, the company said. There also were no serious adverse events observed or discontinuations of treatment occurring because of adverse events during the study. Based on the recent test results, ACHN said it plans to soon move on to another Phase II study of ACH-3102 with and without sofosbuvir as well as decreasing amounts of the experimental protease inhibitor. ACHN shares were ahead nearly 12% at $12.11 apiece, backing down from their session high at $12.85 a share. The stock has traded within a 52-week range of $2.45 to $16.87 a share, already rising nearly 226% over the past 12 months prior to Monday's gain. In other sector news, (+) ATOS, (+34.5%) Signs U.S. distribution agreement with Thermo Fisher Scientific ( TMO ) for its FullCYTE Breast Aspirator device, used by doctors and nurses to collect nipple aspirate fluid for cytological analysis. (-) RGLS, (-7.8%) Said cure rates potentially achievable from a single injection of its RG-101 drug candidate were inferior to other available hepatitis C treatments, with nine of 14 patients measuring below the limits of quantitication after 57 days.
Health Care Sector Update for 02/09/2015: ACHN,ATOS,TMO,RGLS - NASDAQ.com

Results include total product revenue from Lymphoseek of $1.5 million. Navidea's gross profit is expected to be $1.9 million for the quarter and $4.7 million for the year. And, Achillion Pharmaceuticals ( ACHN ) shares were up 11% after a Phase 2 trial of its virus treatment achieved its primary endpoint. Finally, Aurinia Pharmaceuticals ( AUPH ) on Monday said it will initiate an open label, exploratory study to assess the impact of the use of voclosporin in combination with mycophenolate mofetil in patients with active lupus nephritis. The study will examine biomarkers of disease activity at eight weeks and their ability to predict response at 24 and 48 weeks. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc. Copyright (C) 2014 MTNewswires.com.
http://www.nasdaq.com/article/health-care-sector-update-for-02092015-navb-achn-auph-cm441771

Health Care Sector Update for 02/09/2015: NAVB, ACHN, AUPH - NASDAQ.com

In company news, La Jolla Pharmaceutical Co. ( LJPC ) surged Monday after the biotech company and U.S. regulators agreed on a special protocol assessment for Phase III testing of its LJPC-501 drug candidate in patients with a drug-resistant form of low blood pressure. According to the company, the prognosis for patients suffering from catecholamine-resistant hypotension is extremely poor, with fewer than half of those patients surviving one month after diagnosis. Under the special protocol assesment the primary endpoint of the upcoming double-blind, placebo-controlled trial will be an increase in patient blood pressure. The company expects to begin multi-center testing before the end of next month. Final marketing approval of the drug is conditional on the trial results as well as a safety profile and an evaluation of the risk/benefit ratio. LJPC shares were up almost 6% at $18.30 at $18.36 apiece this afternoon, earlier rising to a session high of $18.96 a share.
Health Care Sector Update for 02/09/2015: LJPC,ATOS,TMO,RGLS - NASDAQ.com

Don't be the product, buy the product!

Schweinderl